BPTH (Bio-Path Holdings) Cash per Share : $0.15 (As of Sep. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Bio-Path Holdings's Cash per Share for the quarter that ended in Sep. 2024 was $0.15.

Bio-Path Holdings Cash per Share Historical Data

The historical data trend for Bio-Path Holdings's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings Cash per Share Chart

Bio-Path Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

110.41

60.60

66.41

26.09

1.70

Bio-Path Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash per Share	Get a 7-Day Free Trial															4.11	1.70	0.25	1.76	0.15

Bio-Path Holdings Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Bio-Path Holdings's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	1.052	/	0.62
	=	1.70

Bio-Path Holdings's Cash per Share for the quarter that ended in Sep. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.562	/	3.71
	=	0.15

Bio-Path Holdings (OTCPK:BPTH) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Bio-Path Holdings Cash per Share Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Path Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (OTCPK:BPTH) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401

Website

https://www.biopathholdings.com

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Executives

Aline Sherwood	director	347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen	director	1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese	director	4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen	director, officer: President, CEO & CFO	20651 PRINCE CREEK, KATY TX 77450
Paul Aubert	director	4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver	director	4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller	officer: COO & Secretary	17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison	director	2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris	director	550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read	director	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison	director	P O BOX 150248, OGDEN UT 84415